Grufity logoGrufity logo

Omnicell Inc Stock Research

OMCL

55.52USD+1.24(+2.28%)Market Closed

Market Summary

USD55.52+1.24
Market Closed
2.28%

OMCL Alerts

OMCL Stock Price

OMCL RSI Chart

OMCL Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

439.86

Price/Sales (Trailing)

1.92

EV/EBITDA

25.23

Price/Free Cashflow

82.14

OMCL Price/Sales (Trailing)

OMCL Profitability

EBT Margin

-0.19%

Return on Equity

0.5%

Return on Assets

0.26%

Free Cashflow Yield

1.22%

OMCL Fundamentals

OMCL Revenue

Revenue (TTM)

1.3B

Revenue Y/Y

-4.3%

Revenue Q/Q

-14.48%

OMCL Earnings

Earnings (TTM)

5.6M

Earnings Y/Y

-303.19%

Earnings Q/Q

-269.36%

Price Action

52 Week Range

46.11133.03
(Low)(High)

Last 7 days

-0.4%

Last 30 days

4.8%

Last 90 days

12.9%

Trailing 12 Months

-58.3%

OMCL Financial Health

Current Ratio

2.06

OMCL Investor Care

Shares Dilution (1Y)

1.29%

Diluted EPS (TTM)

0.12

Peers (Alternatives to Omnicell)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.2B
31.5B
-0.19% -16.26%
25
5.73
6.85% 12.06%
105.2B
30.8B
-5.18% -29.10%
25.88
3.42
-3.19% -17.38%
27.9B
-
0.98% 20.75%
47.36
4.81
- -
27.8B
2.1B
7.79% -16.97%
70.06
13.37
17.88% -8.53%
MID-CAP
9.0B
3.5B
11.88% 31.28%
-116.8
2.57
7.15% -34.72%
7.0B
407.9M
-8.38% -7.60%
-156.41
17.21
74.75% -6.75%
4.1B
2.4B
-7.30% -67.14%
-0.3
1.69
18.41% -3085.58%
2.5B
1.3B
4.83% -58.32%
439.86
1.92
14.48% -92.74%
SMALL-CAP
1.6B
262.3M
-14.74% 2.84%
-8.77
6.17
33.16% -131.28%
1.5B
181.0M
14.61% -31.64%
-10.26
8.46
31.19% -48.60%
261.9M
63.1M
-18.62% -64.97%
-24.97
4.15
9.93% -1043.45%
136.8M
357.1M
-19.59% -15.27%
-0.98
0.38
33.22% -57.66%
32.1M
29.3M
-53.48% -70.87%
-2.18
1.1
-19.35% -69.01%
3.4M
6.8M
10.81% 132.08%
-0.15
0.5
-21.00% -36.01%

Financials for Omnicell

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-1.0%1,2961,3091,2581,1991,132
Gross Profit-4.5%589617604582555
Operating Expenses3.9%591569546507465
  S&GA Expenses3.4%486470453423389
  R&D Expenses6.6%10599.0093.0085.0076.00
EBITDA-32.2%84.00125127111-
EBITDA Margin-31.5%0.07*0.10*0.10*0.09*-
Earnings Before Taxes-106.2%-2.4540.0046.0058.0066.00
EBT Margin-106.2%0.00*0.03*0.04*0.05*-
Interest Expenses-2.00----
Net Income-88.2%6.0048.0061.0072.0078.00
Net Income Margin-88.1%0.00*0.04*0.05*0.06*-
Free Cahsflow193.0%30.0010.0038.00123-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.4%2,2112,1802,1312,1232,142
  Current Assets3.8%882849788776781
    Cash Equivalents32.4%353266245265349
  Inventory0.3%148147150137120
  Net PPE6.3%94.0088.0082.0077.0071.00
  Goodwill0.4%734731734740739
Liabilities3.5%1,0811,0441,0391,048996
  Current Liabilities13.7%428377374951876
Shareholder's Equity-0.5%1,1301,1351,0931,0751,147
  Retained Earnings-6.8%391419402393369
  Additional Paid-In Capital1.6%1,0471,0319989831,025
Accumulated Depreciation-5.5%123130126122-
Shares Outstanding0.2%45.0045.0044.0044.0044.00
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations40.8%78.0055.0077.00158232
  Share Based Compensation4.3%68.0065.0062.0058.0053.00
Cashflow From Investing74.9%-58.67-233-411-418-412
Cashflow From Financing-17.4%-20.95-17.85-8.62-0.3547.00
  Buy Backs0%52.0052.0052.0052.000.00

Risks for OMCL

What is the probability of a big loss on OMCL?

81.2%


Probability that Omnicell stock will be more than 20% underwater in next one year

41.9%


Probability that Omnicell stock will be more than 30% underwater in next one year.

18.9%


Probability that Omnicell stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does OMCL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Omnicell was unfortunately bought at previous high price.

Drawdowns

Returns for OMCL

Cumulative Returns on OMCL

11.4%


10-Year Cumulative Returns

10.6%


7-Year Cumulative Returns

5.1%


5-Year Cumulative Returns

-0.8%


3-Year Cumulative Returns

What are the long-term rolling returns for OMCL?

FIve years rolling returns for Omnicell.

Annualized Returns

Which funds bought or sold OMCL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
reduced
-0.68
-1,873,600
2,539,000
0.02%
2023-03-17
American Portfolios Advisors
reduced
-2.99
-93,291
268,662
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-4.58
-1,713,550
2,118,450
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-86.79
-20,800,000
1,722,000
0.01%
2023-02-28
Voya Investment Management LLC
added
103
260,835
1,732,840
-%
2023-02-24
NATIXIS
added
92.73
57,737
754,737
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-12.32
-1,152,000
1,191,000
0.01%
2023-02-21
NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC
reduced
-35.39
-348,614
208,386
0.01%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
1.14
-145,682
206,318
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-40.28
-68,774,000
36,364,000
0.04%

1–10 of 42

Latest Funds Activity

Are funds buying OMCL calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own OMCL
No. of Funds

Omnicell News

Yahoo Finance

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now.

Yahoo Finance,
17 hours ago

InvestorsObserver

Yahoo Finance

Should You Hold Omnicell (OMCL)?.

Yahoo Finance,
10 days ago

Yahoo Finance

Seeking Alpha

Schedule 13G FIlings of Omnicell

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.92%
4,430,315
SC 13G/A
Feb 06, 2023
wellington management group llp
7.34%
3,277,600
SC 13G/A
Jan 23, 2023
blackrock inc.
12.8%
5,728,315
SC 13G/A
Feb 10, 2022
vanguard group inc
10.79%
4,740,493
SC 13G/A
Feb 04, 2022
wellington management group llp
5.76%
2,531,555
SC 13G/A
Jan 27, 2022
blackrock inc.
15.9%
6,983,442
SC 13G/A
Jan 26, 2022
blackrock inc.
15.9%
6,983,442
SC 13G/A
Feb 10, 2021
vanguard group inc
10.62%
4,492,384
SC 13G/A
Feb 05, 2021
blackrock inc.
15.7%
6,663,069
SC 13G/A
Jan 11, 2021
wellington management group llp
6.04%
2,555,699
SC 13G/A

OMCL Fair Value

Omnicell fair value in different scenarios

The table shows the Fair Value estimates for Omnicell for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

26.61

-52.07%

32.03

-42.31%

42.64

-23.20%

57.13

2.90%

67.72

21.97%
Current Inflation

24.79

-55.35%

29.39

-47.06%

38.30

-31.02%

50.45

-9.13%

59.26

6.74%
Very High Inflation

22.54

-59.40%

26.20

-52.81%

33.19

-40.22%

42.70

-23.09%

49.55

-10.75%

Historical Omnicell Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Omnicell

View All Filings
Date Filed Form Type Document
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 01, 2023
10-K
Annual Report
Feb 28, 2023
8-K
Current Report
Feb 17, 2023
4
Insider Trading
Feb 14, 2023
5
Insider Trading
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 06, 2023
SC 13G/A
Major Ownership Report
Jan 23, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for OMCL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-15
SPEARS JOSEPH BRIAN
sold (taxes)
-6,023
55.26
-109
chief accounting officer & svp
2023-03-15
Manley Corey J
sold (taxes)
-4,586
55.26
-83.00
sr. vp & chief legal officer
2023-03-07
Bauer Joanne B
sold
-711,333
54.2381
-13,115
-
2023-03-07
Bauer Joanne B
acquired
493,469
25.53
19,329
-
2023-02-15
SPEARS JOSEPH BRIAN
sold (taxes)
-3,259
55.25
-59.00
chief accounting officer & svp
2022-12-28
PARRISH MARK W
acquired
44,610
14.87
3,000
-
2022-12-27
Seidelmann Scott Peter
sold
-45,624
48.28
-945
evp, chief commercial officer
2022-12-22
PARRISH MARK W
acquired
44,610
14.87
3,000
-
2022-12-16
Seidelmann Scott Peter
sold
-211,990
47.7885
-4,436
evp, chief commercial officer
2022-12-15
Manley Corey J
sold (taxes)
-10,753
48.44
-222
sr. vp & chief legal officer

1–10 of 50

Randall A. Lipps
3800
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

OMCL Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues$ 1,295,947$ 1,132,018$ 892,208
Cost of revenues706,960577,365478,916
Gross profit588,987554,653413,292
Operating expenses:   
Research and development104,96975,71670,161
Selling, general, and administrative486,341389,430307,605
Total operating expenses591,310465,146377,766
Income (loss) from operations(2,323)89,50735,526
Interest and other income (expense), net(130)(23,500)(6,177)
Income (loss) before provision for income taxes(2,453)66,00729,349
Benefit from income taxes(8,101)(11,842)(2,845)
Net income$ 5,648$ 77,849$ 32,194
Net income per share:   
Basic (in dollars per share)$ 0.13$ 1.79$ 0.76
Diluted (in dollars per share)$ 0.12$ 1.62$ 0.74
Weighted-average shares outstanding:   
Basic (in shares)44,39843,47542,583
Diluted (in shares)45,89147,94343,743
Product revenues   
Revenues$ 903,222$ 812,512$ 636,031
Cost of revenues493,626422,855354,004
Services and other revenues   
Revenues392,725319,506256,177
Cost of revenues$ 213,334$ 154,510$ 124,912

OMCL Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
shares in Thousands, $ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 330,362$ 349,051
Accounts receivable and unbilled receivables, net of allowances of $5,153 and $5,272, respectively299,469240,894
Inventories147,549119,924
Prepaid expenses27,07022,499
Other current assets77,36248,334
Total current assets881,812780,702
Property and equipment, net93,96171,141
Long-term investment in sales-type leases, net32,92418,391
Operating lease right-of-use assets38,05248,549
Goodwill734,274738,900
Intangible assets, net242,906277,616
Long-term deferred tax assets22,32915,883
Prepaid commissions59,48363,795
Other long-term assets105,017127,519
Total assets2,210,7582,142,496
Current liabilities:  
Accounts payable63,38971,513
Accrued compensation73,45571,130
Accrued liabilities172,655133,167
Deferred revenues, net118,947112,196
Convertible senior notes, net0488,152
Total current liabilities428,446876,158
Long-term deferred revenues37,38520,194
Long-term deferred tax liabilities2,09551,705
Long-term operating lease liabilities39,40539,911
Other long-term liabilities6,7197,839
Convertible senior notes, net566,5710
Total liabilities1,080,621995,807
Commitments and contingencies (Note 14)
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued00
Common stock, $0.001 par value, 100,000 shares authorized; 55,030 and 54,073 shares issued; 44,747 and 44,179 shares outstanding, respectively5554
Treasury stock at cost, 10,283 and 9,894 shares outstanding, respectively(290,319)(238,109)
Additional paid-in capital1,046,7601,024,580
Retained earnings390,728368,571
Accumulated other comprehensive loss(17,087)(8,407)
Total stockholders’ equity1,130,1371,146,689
Total liabilities and stockholders’ equity$ 2,210,758$ 2,142,496
Treasury stock, shares outstanding (in shares)10,2839,894